阿尔茨海默病严重程度的全球社会负担：一项有针对性的文献综述

IF 4.8 3区医学 Q1 CLINICAL NEUROLOGY

Neurology and Therapy Pub Date : 2025-10-01 Epub Date: 2025-08-27 DOI:10.1007/s40120-025-00815-w

Maria A Cavaco, Se Ryeong Jang, Christopher Olsen, Carolyn Bodnar, Nicole Ferko

{"title":"阿尔茨海默病严重程度的全球社会负担：一项有针对性的文献综述","authors":"Maria A Cavaco, Se Ryeong Jang, Christopher Olsen, Carolyn Bodnar, Nicole Ferko","doi":"10.1007/s40120-025-00815-w","DOIUrl":null,"url":null,"abstract":"Introduction: Alzheimer's disease (AD) is among the costliest of illnesses for the elderly, placing a significant burden on healthcare systems and caregivers. Despite the depth of evidence, reviews lack a holistic assessment of such costs, falling short of illustrating unmet medical needs. The objective of this review was to therefore characterize the total societal economic burden of AD, broken down by care setting and disease severity.Methods: A targeted literature search of systematic reviews, cost-of-illness, and observational studies published between 2013 and 2024 was conducted on MEDLINE and Embase to identify articles reporting the economic burden of AD. Grey literature was hand-searched. Both direct and indirect costs were assessed, including societal burdens not often reported by AD-specific cost-of-illness studies such as financial delinquencies.Results: In total, 81 articles were reviewed in depth, including 20 systematic reviews and 61 studies or reports. Findings consistently demonstrated that societal costs of AD or dementia typically increased by at least 50% between consecutive severity levels, increasing with disease progression. Informal caregiving often comprised close to half of societal costs, regardless of care setting, disease severity, or region. While studies reporting costs of mild cognitive impairment (MCI) were limited, the economic burden reported for this stage was appreciable compared to mild AD. Evidence for the impact of AD, as early as MCI, on quality of life (e.g., emotional and mental strain) and personal financial management capabilities was also identified.Conclusion: This review provides a comprehensive overview, from studies spanning over more than a decade, of the substantial societal economic burden associated with AD, across cost categories, care settings, disease stages, and regions. This review may be used to inform health economic evaluations of novel interventions with potential to reduce the enormous and growing global economic burden of AD and dementia.","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":"1797-1826"},"PeriodicalIF":4.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450196/pdf/","citationCount":"0","resultStr":"{\"title\":\"Global Societal Burden of Alzheimer's Disease by Severity: a Targeted Literature Review.\",\"authors\":\"Maria A Cavaco, Se Ryeong Jang, Christopher Olsen, Carolyn Bodnar, Nicole Ferko\",\"doi\":\"10.1007/s40120-025-00815-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Alzheimer's disease (AD) is among the costliest of illnesses for the elderly, placing a significant burden on healthcare systems and caregivers. Despite the depth of evidence, reviews lack a holistic assessment of such costs, falling short of illustrating unmet medical needs. The objective of this review was to therefore characterize the total societal economic burden of AD, broken down by care setting and disease severity.Methods: A targeted literature search of systematic reviews, cost-of-illness, and observational studies published between 2013 and 2024 was conducted on MEDLINE and Embase to identify articles reporting the economic burden of AD. Grey literature was hand-searched. Both direct and indirect costs were assessed, including societal burdens not often reported by AD-specific cost-of-illness studies such as financial delinquencies.Results: In total, 81 articles were reviewed in depth, including 20 systematic reviews and 61 studies or reports. Findings consistently demonstrated that societal costs of AD or dementia typically increased by at least 50% between consecutive severity levels, increasing with disease progression. Informal caregiving often comprised close to half of societal costs, regardless of care setting, disease severity, or region. While studies reporting costs of mild cognitive impairment (MCI) were limited, the economic burden reported for this stage was appreciable compared to mild AD. Evidence for the impact of AD, as early as MCI, on quality of life (e.g., emotional and mental strain) and personal financial management capabilities was also identified.Conclusion: This review provides a comprehensive overview, from studies spanning over more than a decade, of the substantial societal economic burden associated with AD, across cost categories, care settings, disease stages, and regions. This review may be used to inform health economic evaluations of novel interventions with potential to reduce the enormous and growing global economic burden of AD and dementia.\",\"PeriodicalId\":19216,\"journal\":{\"name\":\"Neurology and Therapy\",\"volume\":\" \",\"pages\":\"1797-1826\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450196/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurology and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40120-025-00815-w\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40120-025-00815-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

阿尔茨海默病（AD）是老年人最昂贵的疾病之一，给卫生保健系统和护理人员带来了沉重负担。尽管证据丰富，但审查缺乏对这些费用的全面评估，无法说明未满足的医疗需求。因此，本综述的目的是描述阿尔茨海默病的社会经济总负担，并按护理环境和疾病严重程度分类。方法：在MEDLINE和Embase上对2013年至2024年间发表的系统评价、疾病成本和观察性研究进行有针对性的文献检索，以确定报道AD经济负担的文章。灰色文献是手工搜索的。评估了直接和间接成本，包括ad特定疾病成本研究中不经常报告的社会负担，如金融违约。结果：共深入综述81篇，其中系统综述20篇，研究或报告61篇。研究结果一致表明，阿尔茨海默病或痴呆症的社会成本在连续严重程度之间通常增加至少50%，并随着疾病进展而增加。无论护理环境、疾病严重程度或地区如何，非正式护理往往占社会成本的近一半。虽然报道轻度认知障碍（MCI）成本的研究有限，但与轻度AD相比，这一阶段的经济负担是可观的。研究还发现，早在MCI阶段，AD就对生活质量（如情绪和精神紧张）和个人财务管理能力产生了影响。结论：本综述从十多年来的研究中全面概述了与AD相关的重大社会经济负担，包括成本类别、护理环境、疾病阶段和地区。这篇综述可用于对有可能减轻阿尔茨海默病和痴呆症巨大且日益增长的全球经济负担的新干预措施进行健康经济评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Global Societal Burden of Alzheimer's Disease by Severity: a Targeted Literature Review.

Introduction: Alzheimer's disease (AD) is among the costliest of illnesses for the elderly, placing a significant burden on healthcare systems and caregivers. Despite the depth of evidence, reviews lack a holistic assessment of such costs, falling short of illustrating unmet medical needs. The objective of this review was to therefore characterize the total societal economic burden of AD, broken down by care setting and disease severity.

Methods: A targeted literature search of systematic reviews, cost-of-illness, and observational studies published between 2013 and 2024 was conducted on MEDLINE and Embase to identify articles reporting the economic burden of AD. Grey literature was hand-searched. Both direct and indirect costs were assessed, including societal burdens not often reported by AD-specific cost-of-illness studies such as financial delinquencies.

Results: In total, 81 articles were reviewed in depth, including 20 systematic reviews and 61 studies or reports. Findings consistently demonstrated that societal costs of AD or dementia typically increased by at least 50% between consecutive severity levels, increasing with disease progression. Informal caregiving often comprised close to half of societal costs, regardless of care setting, disease severity, or region. While studies reporting costs of mild cognitive impairment (MCI) were limited, the economic burden reported for this stage was appreciable compared to mild AD. Evidence for the impact of AD, as early as MCI, on quality of life (e.g., emotional and mental strain) and personal financial management capabilities was also identified.

Conclusion: This review provides a comprehensive overview, from studies spanning over more than a decade, of the substantial societal economic burden associated with AD, across cost categories, care settings, disease stages, and regions. This review may be used to inform health economic evaluations of novel interventions with potential to reduce the enormous and growing global economic burden of AD and dementia.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Neurology and Therapy CLINICAL NEUROLOGY-

CiteScore

5.40

自引率

8.10%

发文量

103

审稿时长

6 weeks

期刊介绍： Aims and Scope Neurology and Therapy aims to provide reliable and inclusive, rapid publication for all therapy related research for neurological indications, supporting the timely dissemination of research with a global reach, to help advance scientific discovery and support clinical practice. Neurology and Therapy is an international, open access, peer reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world and health outcomes research around the discovery, development, and use of neurological and psychiatric therapies, (also covering surgery and devices). Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also welcomed. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, case reports, trial designs, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Neurology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Rapid Publication The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted, it will be published online 3-4 weeks from acceptance. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model, this allows for the rapid and efficient communication of the latest research and reviews to support scientific discovery and clinical practice. Open Access All articles published by Neurology and Therapy are open access. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts. Digital Features and Plain Language Summaries Neurology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. For examples of digital features please visit our showcase page https://springerhealthcare.com/expertise/publishing-digital-features/ Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5250/$6000/£4300. The journal will consider fee discounts and waivers for developing countries and this is decided on a case-by-case basis. Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials and Letters which are generally reviewed by one member of the Editorial Board. Where reviews conflict, an Editorial Board Member will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed. Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised, it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor, and authors are welcome to make rebuttals against individual reviewer comments, if appropriate. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors'' or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Please see here for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Copyright Neurology and Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0. Contact For more information about the journal, including pre-submission enquiries, please contact managing editor Lydia Alborn at lydia.alborn@springer.com.